FDA Updates: Real-Life Proof for Medical Gadgets
Published Date: 12/18/2025
Notice
Summary
The FDA just released updated rules on how real-world data can help approve medical devices faster and smarter. This affects medical device makers and FDA staff by giving clearer, better ways to use everyday health info for decisions. The new guidance starts December 18, 2025, aiming to speed up approvals without extra costs.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Clarifies use of real‑world data
If you are a medical device sponsor or manufacturer, FDA issued final guidance on December 18, 2025 that explains how FDA evaluates real‑world data (RWD) to determine whether they are good enough to generate real‑world evidence (RWE) for regulatory decision‑making. The guidance updates and expands the 2017 RWE guidance and gives recommendations on when RWD sources and study approaches are relevant and reliable.
EUA and CLIA data usability clarified
The guidance provides additional clarity about using clinical data collected from devices authorized under an Emergency Use Authorization (EUA) and describes what types of information could be applicable to support Clinical Laboratory Improvement Amendments (CLIA) determinations, such as a Waiver by Application. This helps sponsors know when EUA‑collected data might be acceptable for certain regulatory or CLIA decisions.
60‑day operational transition period
FDA recognizes that the Agency and industry may need up to 60 days to operationalize the recommendations in this final guidance. For submissions pending after publication on December 18, 2025, and for submissions received within 60 days following that date, FDA generally does not expect sponsors to already include the newly recommended information, though FDA will review any such information if it is submitted.
No new paperwork collections required
The guidance states it contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved FDA collections with listed OMB control numbers. That means the guidance itself does not add new PRA reporting requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2025-23251 — Submission for OMB Review; 30-Day Comment Request; Special Volunteer and Guest Researcher Assignment (Office of Intramural Research, Office of the Director)
The NIH is asking for a 30-day public comment on their request to keep collecting info from special volunteers and guest researchers. This affects people who work or volunteer in NIH research programs and won’t cost anyone extra money. They want to make sure their forms stay approved and easy to use, so the research keeps running smoothly.
Next: 2025-23255 — Performance Review Board Membership
The USDA just announced the new team members for its Performance Review Boards starting November 18, 2025. These boards help decide how top executives get rated and rewarded, making sure everything’s fair and by the book. If you’re a senior leader at USDA, this update affects how your performance and pay get reviewed.